# Semaglutide for Diabetes vs. Weight Loss: What's Actually Different?
Patients and physicians alike get confused by this: Ozempic and Wegovy are both semaglutide. They're made by the same company (Novo Nordisk), contain the same active ingredient, and work the same way. Yet they're approved for different indications at different prices.
This isn't a coincidence — it reflects how drug approvals work and why dose matters for different goals.
The Same Drug, Different Approvals
Ozempic (semaglutide 0.25mg, 0.5mg, 1mg, 2mg weekly injection): - FDA-approved for: type 2 diabetes (blood sugar management) and cardiovascular risk reduction in adults with type 2 diabetes and cardiovascular disease - Not approved for weight loss as a primary indication - Maximum approved dose: 2mg/week for diabetes
Wegovy (semaglutide 0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg weekly injection): - FDA-approved for: chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity - Titrates to 2.4mg (higher than Ozempic's max) - Not approved for type 2 diabetes as a primary indication
Both contain semaglutide. The difference is the target dose and the indication for which Novo Nordisk ran the clinical trials and obtained regulatory approval.
Why Does the Higher Dose Matter?
In the STEP trials for weight management, higher doses of semaglutide produced more weight loss: - 1mg weekly: ~7% weight loss - 2.4mg weekly (Wegovy dose): ~15-17% weight loss
That's more than double the weight loss from roughly double the dose.
For type 2 diabetes management, 1-2mg is sufficient to meaningfully improve HbA1c and blood glucose — you don't need 2.4mg. But for weight management, the higher dose produces dramatically better outcomes.
This is why Novo Nordisk ran separate trials at 2.4mg and sought a separate approval for Wegovy — the dose is clinically meaningful.
Blood Sugar Effects on Both
Here's the interesting part: both Ozempic and Wegovy lower blood glucose, even though only Ozempic is approved for diabetes.
Semaglutide's mechanism of action: - Increases insulin secretion in a glucose-dependent manner (releases insulin when blood sugar rises) - Decreases glucagon secretion (reduces liver glucose output) - Slows gastric emptying (blunts post-meal blood glucose spikes)
These effects are present at all doses. Wegovy patients (without diabetes) experience meaningfully improved insulin sensitivity and blood glucose regulation — it just isn't the primary approved indication.
Similarly, many Ozempic-prescribed patients with diabetes also lose weight — though not as much as on Wegovy doses.
Who Gets Which Drug?
Ozempic is prescribed to patients who: - Have type 2 diabetes requiring blood sugar management - Have established cardiovascular disease and type 2 diabetes (cardiovascular risk indication) - May also benefit from weight loss, but diabetes management is the primary goal
Wegovy is prescribed to patients who: - Have obesity (BMI ≥30) - Have overweight (BMI ≥27) with a weight-related condition (hypertension, type 2 diabetes, high cholesterol, obstructive sleep apnea, cardiovascular disease) - Want dedicated weight management with the highest-efficacy dose
What about "off-label" prescribing? Ozempic is commonly prescribed for weight loss "off-label" — meaning outside its approved indication. This is legal and common medical practice. Many patients received Ozempic for weight loss before Wegovy was approved or widely available. Some still do because Ozempic can be cheaper with insurance coverage for diabetes.
Compounded Semaglutide: The Third Category
Compounded semaglutide (available through telehealth providers like Marrow) uses the same active pharmaceutical ingredient as both Ozempic and Wegovy, prepared by FDA-registered 503B compounding pharmacies.
Compounded semaglutide is typically dosed to match or approach Wegovy's weight loss protocol (titrating toward 2.4mg) while costing significantly less than either brand-name option.
| Product | Indication | Max Dose | Price/Month | |---|---|---|---| | Ozempic | Type 2 diabetes | 2mg | $900-1,100 | | Wegovy | Weight management | 2.4mg | $1,300-1,600 | | Compounded semaglutide (Marrow) | Weight management | Physician-guided | From $249 |
The Cardiovascular Win
One of the most significant recent developments: SELECT trial data (2023) showed semaglutide 2.4mg reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in patients with obesity and established cardiovascular disease — even without diabetes.
This expanded the FDA approval of Wegovy to include cardiovascular risk reduction, making it the first weight-loss medication to demonstrate meaningful cardiovascular outcome benefits. The drug is now used not just for weight, but as a cardiovascular therapy in its own right.
Practical Takeaway
If you have type 2 diabetes and need blood sugar management: Ozempic (or generic semaglutide for diabetes) is the relevant product.
If your primary goal is weight loss: Wegovy dosing (titrating toward 2.4mg) produces significantly better outcomes. Compounded semaglutide at Wegovy-equivalent doses is a cost-effective option.
If you have both: The same drug addresses both goals. Your physician can optimize dose for your primary objective — and the secondary benefits follow.
At Marrow, we prescribe semaglutide for weight management with physician oversight and titration guidance. [See if you qualify →](/start)
Frequently Asked Questions
Is Ozempic or Wegovy better for weight loss?
Wegovy — because it titrates to a higher dose (2.4mg vs. Ozempic's max of 2mg for diabetes). Higher semaglutide doses produce more weight loss: about 15-17% at Wegovy's 2.4mg dose vs. approximately 7% at 1mg. The same active ingredient is in both drugs, but dose is the key variable for weight loss efficacy. Compounded semaglutide, available at significantly lower cost, can be dosed to match Wegovy's protocol.
Can you use Ozempic for weight loss if you don't have diabetes?
Yes — physicians frequently prescribe Ozempic off-label for weight loss in patients without diabetes. This is legal and common practice. However, Ozempic maxes out at 2mg (vs. Wegovy's 2.4mg), and the 1-2mg doses produce less weight loss than the Wegovy-specific protocol. If weight loss is the primary goal and cost/coverage allows, Wegovy (or compounded semaglutide at Wegovy-equivalent dosing) is typically more effective.
Does semaglutide for weight loss affect blood sugar in people without diabetes?
Yes. Semaglutide improves insulin sensitivity and blood glucose regulation through its mechanism of action regardless of diabetes status. Patients without diabetes who take semaglutide experience improved insulin sensitivity, lower fasting glucose, and better post-meal blood sugar control. These metabolic improvements are real — they just aren't the primary approved indication for Wegovy.
How much does semaglutide for weight loss cost without insurance?
Brand-name Wegovy costs $1,300-1,600/month without insurance. Brand-name Ozempic costs $900-1,100/month. Compounded semaglutide through providers like Marrow — using the same active pharmaceutical ingredient from FDA-registered pharmacies — starts at $249/month, making it accessible for patients paying out of pocket. Insurance coverage for weight loss medications remains inconsistent; compounded options are the most common pathway for uninsured patients.
Get our free Body Composition Guide
Protein protocols, workout structure, sleep optimization, and the supplement stack that actually works.
Get our free Body Composition Guide →
